舒血宁注射液干预急性心肌梗死介入治疗患者血浆糖原合成酶激酶3β水平的变化  

Changes in plasma glycogen synthase kinase-3 beta in patients with acute myocardial infarction following percutaneous coronary intervention and the effect of Shuxuening parenteral solution

作　　者：钮炜西[1] 华宁[1] 齐帜[1] 

机构地区：[1]解放军总医院第二附属医院心血管内科,北京市100091

出　　处：《中国组织工程研究与临床康复》2007年第12期2233-2236,共4页Journal of Clinical Rehabilitative Tissue Engineering Research

摘　　要：目的:观察急性心肌梗死经皮冠脉内介入治疗患者血浆糖原合成酶激酶3β及脂质过氧化反应水平变化及舒血宁注射液的干预作用。方法:选取2004-11/2005-09在解放军总医院行急诊经皮冠脉内介入治疗的急性心肌梗死患者45例。随机数字表法分为舒血宁组23例,男15例,女8例,平均年龄(56.8±10.3)岁。在经皮冠脉内介入治疗基础上加用舒血宁注射液40mL静脉注射,1次/d,共7d。对照组22例,男13例,女9例;平均年龄(55.3±11.5)岁。行经皮冠脉内介入治疗,另取15例健康人血浆为正常对照,平均年龄(52.3±8.3)岁。分别应用ELISA法、分光光度计法、聚合酶链反应法和western blotting法,检测患者入院时及术后第1,3,7天的血浆糖原合成酶激酶3β、肿瘤坏死因子α、白细胞介素6、超氧化物歧化酶、丙二醛水平。结果:45例患者、15名正常人全部进入结果分析。①血浆糖原合成酶激酶3βmRNA及糖原合成酶激酶3β蛋白含量:舒血宁组和对照组患者入院时、术后1d较正常组升高;术后3d和7d舒血宁组低于对照组(3d:0.224±0.023比0.321±0.036,0.401±0.044比0.524±0.054;7d:0.186±0.021比0.245±0.033,0.154±0.025比0.215±0.022,P<0.01)。②血浆超氧化物歧化酶、丙二醛及肿瘤坏死因子α、白细胞介素6水平:舒血宁组和对照组患者入院时、术后1d血浆白细胞介素6、肿瘤坏死因子α、丙二醛水平均高于正常组;术后3d和7d患者血浆白细胞介素6、肿瘤坏死因子α、丙二醛水平显著降低,舒血宁组低于对照组,超氧化物歧化酶活性高于对照组。结论:心肌梗死经皮冠脉内介入治疗患者血浆糖原合成酶激酶3βmRNA及蛋白水平呈先上升后下降的趋势,舒血宁注射液能减轻再灌注损伤,具有心肌保护作用,该作用可能与血浆糖原合成酶激酶3βmRNA及蛋白调节有关。AIM： To investigate changes of glycogen synthase kinase （GSK）-3β in the plasm and the level of lipid peroxidatic reaction in patients of acute myocardial infarction treated with percutaneous coronary intervention （PCI） and the effect of Shuxuening parenteral solution on them. METHODS： A total of 45 patients of acute myocardial infarction treated with PCI were enrolled from General Hospital of Chinese PLA from November 2004 to September 2005. They were randomly classified into treatment group （n =23） including 15 males and 8 females, with an average of （56.8±10.3） years. On the basis of PCI, 40 mL Shuxuening was injected into vein, once a day, for 7 days. Control group （n =22） included 13 males and 9 females, with an average of （55.3±11.5） years. They were treated with PCI only. Another 15 healthy persons were included in the normal control group, with an average of （52.3±8.3） years. ELISA, spectrophotometer detection, polymerase chain reaction （PCR） and western blotting were used to detect the levels of GSK3β, tumor necrosis factor （TNF）-α, intedeukin （IL）-6, superoxide dismutase （SOD） and malondialdehyde （MDA） in the plasma at the time of hospitalization, 1, 3 and 7 days after operation. RESULTS： Totally 45 patients and 15 normal persons were involved in the result analysis. （1）Contents of GSK3β mRNA and GSK3β protein in plasma： The contents increased in the treatment group and control group at the time of hospitalization and day 1 after operation than the normal group. The contents were lower in the treatment group at days 3 and 7 after operation than the control group （at day 3：0.224±0.023 vs 0.321±0.036,0.401±0.044 vs 0.524±0.054;day 7：0.186±0.021 vs 0.245±0.033,0.154±0.025 vs 0.215±0.022,P 〈 0.01 ）. （2）Levels of SOD, MDA, TNF-α and IL-6 in plasma： The levels of IL-6, MDA and TNF-α in the treatment group and control group were higher than those in the normal group at the time of hospitalization and days 1 after opera

关 键 词：糖原合成酶激酶3 心肌梗塞 肿瘤坏死因子Α 丙二醛 

分 类 号：R542.2[医药卫生—心血管疾病]